Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

1,003.57
-4.1600-0.41%
Post-market: 1,005.001.43+0.14%19:59 EST
Volume:1.97M
Turnover:1.97B
Market Cap:948.76B
PE:43.73
High:1,015.66
Open:1,011.63
Low:993.66
Close:1,007.73
52wk High:1,133.95
52wk Low:623.78
Shares:945.38M
Float Shares:945.00M
Volume Ratio:0.64
T/O Rate:0.21%
Dividend:6.00
Dividend Rate:0.60%
EPS(TTM):22.95
EPS(LYR):22.95
ROE:101.16%
ROA:19.42%
PB:35.75
PE(LYR):43.73

Loading ...

Dow Jones Top Company Headlines at 9 PM ET: Novo Nordisk Escalates Fight Against Hims & Hers | On ...

Dow Jones
·
Feb 10

Top News Today: Stocks Rise as AI, Crypto Fears Subside

Dow Jones
·
Feb 10

Top Midday Stories: Novo Nordisk Sues Hims for Alleged Patent Infringement; Transocean to Acquire Valaris for $5.8 Billion

MT Newswires Live
·
Feb 10

Eli Lilly Shares Climb Over 3% on Acquisition of Immune Cell Engineering Firm Orna Therapeutics

Stock News
·
Feb 09

Eli Lilly To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Monday

Benzinga_recent_news
·
Feb 09

BRIEF-Lilly Q4 Adjusted EPS USD 7.54 Vs. IBES Estimate USD 6.67 (Feb. 4)

Reuters
·
Feb 09

Argus Adjusts Price Target on Eli Lilly and Company to $1,200 From $930, Maintains Buy Rating

MT Newswires Live
·
Feb 09

Eli Lilly Is Maintained at Buy by Deutsche Bank

Dow Jones
·
Feb 09

Lilly To Buy Orna Therapeutics For Up To $2.4 Billion

Reuters
·
Feb 09

Eli Lilly : Argus Research Raises Target Price to $1200 From $930

THOMSON REUTERS
·
Feb 09

Corrected-Eli Lilly & Co. : Morgan Stanley Raises Target Price to $1,313 From $1290 (Not to $1290.00 From $24.20) (Feb 5)

THOMSON REUTERS
·
Feb 09

Eli Lilly to Buy Immune Cell Engineering Company Orna Therapeutics

MT Newswires Live
·
Feb 09

BRIEF-Lilly To Acquire Orna Therapeutics To Advance Cell Therapies

Reuters
·
Feb 09

Eli Lilly übernimmt Orna Therapeutics für bis zu 2,4 Milliarden Dollar

Reuters
·
Feb 09

Eli Lilly - Orna Shareholders to Receive up to $2.4 Bln in Cash

THOMSON REUTERS
·
Feb 09

Lilly to Acquire Orna Therapeutics to Advance Cell Therapies

THOMSON REUTERS
·
Feb 09

Eli Lilly Shares up 2.2% Premarket After Hims & Hers Withdraws Launch of Weight-Loss Pill

THOMSON REUTERS
·
Feb 09

Strong Weight-Loss Drug Demand Fuels Optimistic Growth Outlook! Goldman Sachs Raises Eli Lilly Target to $1,260

Stock News
·
Feb 09

24H | Eli Lilly Stock Jumps Nearly 2% as Lilly Inks Deal with Innovent to Speed Up Early Drug Development

Tiger Newspress
·
Feb 09

Bristol Gate Capital Partners Trims Eli Lilly Stake

TIPRANKS
·
Feb 09